Working... Menu

A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02092922
Recruitment Status : Completed
First Posted : March 20, 2014
Last Update Posted : October 6, 2017
Information provided by (Responsible Party):
Array BioPharma

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : July 2016
  Actual Study Completion Date : September 5, 2017
  Certification/Extension First Submitted : August 7, 2017